Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Cancer Sci ; 115(5): 1459-1475, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38433526

RESUMO

Antiangiogenic therapy targeting VEGF-A has become the standard of first-line therapy for non-small cell lung cancer (NSCLC). However, its clinical response rate is still less than 50%, and most patients eventually develop resistance, even when using combination therapy with chemotherapy. The major cause of resistance is the activation of complex bypass signals that induce angiogenesis and tumor progression. Therefore, exploring novel proangiogenic mechanisms and developing promising targets for combination therapy are crucial for improving the efficacy of antiangiogenic therapy. Immunoglobulin-like transcript (ILT) 4 is a classic immunosuppressive molecule that inhibits myeloid cell activation. Recent studies have shown that tumor cell-derived ILT4 drives tumor progression via the induction of malignant biologies and creation of an immunosuppressive microenvironment. However, whether and how ILT4 participates in NSCLC angiogenesis remain elusive. Herein, we found that enriched ILT4 in NSCLC is positively correlated with high microvessel density, advanced disease, and poor overall survival. Tumor cell-derived ILT4 induced angiogenesis both in vitro and in vivo and tumor progression and metastasis in vivo. Mechanistically, ILT4 was upregulated by its ligand angiopoietin-like protein 2 (ANGPTL2). Their interaction subsequently activated the ERK1/2 signaling pathway to increase the secretion of the proangiogenic factors VEGF-A and MMP-9, which are responsible for NSCLC angiogenesis. Our study explored a novel mechanism for ILT4-induced tumor progression and provided a potential target for antiangiogenic therapy in NSCLC.


Assuntos
Carcinoma Pulmonar de Células não Pequenas , Neoplasias Pulmonares , Neovascularização Patológica , Receptores Imunológicos , Carcinoma Pulmonar de Células não Pequenas/patologia , Carcinoma Pulmonar de Células não Pequenas/metabolismo , Carcinoma Pulmonar de Células não Pequenas/irrigação sanguínea , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Humanos , Neoplasias Pulmonares/patologia , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/irrigação sanguínea , Neoplasias Pulmonares/tratamento farmacológico , Neovascularização Patológica/metabolismo , Neovascularização Patológica/patologia , Animais , Camundongos , Linhagem Celular Tumoral , Receptores Imunológicos/metabolismo , Feminino , Masculino , Glicoproteínas de Membrana/metabolismo , Sistema de Sinalização das MAP Quinases , Metaloproteinase 9 da Matriz/metabolismo , Regulação Neoplásica da Expressão Gênica , Fator A de Crescimento do Endotélio Vascular/metabolismo , Microambiente Tumoral , Angiogênese
2.
J Chem Phys ; 127(15): 154106, 2007 Oct 21.
Artigo em Inglês | MEDLINE | ID: mdl-17949131

RESUMO

In this short paper, we introduce an approximate method for the quick estimate of rate constants based on a simple sampling method of reactive transition paths over high energy barriers. It makes use of the previously introduced accelerated molecular dynamics (MD) simulation method to generate initial points for trajectory shooting. The accelerated MD simulations, although with the loss of real dynamics, lead to a quick calculation of thermodynamic properties and at the same time produce an ensemble of configurations with an enhanced sampling over the phase space that is more "reactive." The forward/backward trajectory shooting as that used in the transition path sampling method is then initiated from the configurations obtained from accelerated MD simulations to generate transition paths on the original unbiased potential. This method selectively enhances sampling of successful trajectories and at the same time accelerates significantly the calculation of rate constants.

SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa